There are many treatments for endometrial cancer, and the choice of treatment will depend on the extent (stage) of your disease along with other things. Jemperli is a treatment for endometrial cancer.

GSK has claimed US approval for Jemperli alongside chemotherapy for previously untreated, primary advanced or recurrent endometrial cancer, becoming the first immunotherapy option for first-line ...

The U.S. Food and Drug Administration (FDA) has approved a new drug for certain adult patients with endometrial cancer. Jemperli (dostarlimab-gxly) — made by British pharmaceutical company GSK ...

GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug. The latest readout from the ...

Immunotherapy drugs approved to treat endometrial cancer are: Dostarlimab (Jemperli) Durvalumab (Imfinzi) Pembrolizumab (Keytruda) Your doctor may check your tumor cells for certain ...

On Thursday, the FDA expanded the endometrial cancer use for GSK’s Jemperli, used in combination with chemotherapy, to include patients with mismatch repair proficient (pMMR) or microsatellite ...

FDA approval for Jemperli plus chemotherapy was expanded to include all adult patients with primary advanced or recurrent endometrial cancer in August 2024. More on GSK GSK plc (GSK) 43rd Annual J ...

With this approval, Jemperli is now indicated earlier in treatment, in combination with chemotherapy, for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer. Jemperli has ...

Jemperli was approved for similar expanded use in endometrial cancer in the United States in August 2024. The drug is also approved for second-line endometrial cancer and dMMR recurrent or ...

GSK’sGSK-0.21%decrease; red down pointing triangle cancer drug Jemperli cleared an important ... of adult patients with primary or recurrent endometrial cancer who are candidates for systemic ...